The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Anastasilakis, A. D., Makras P., Polyzos S. A., & Papapoulos S. E. (2023).  The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.. Calcif Tissue Int.
Anastasilakis, A. D., Trovas G., Balanika A., Polyzos S. A., Makras P., & Tournis S. (2020).  Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.. J Clin Densitom.
Anastasilakis, K., Mourgela A., Symeonidis C., Dimitrakos S. A., Ekonomidis P., & Tsinopoulos I. (2015).  Macular edema after uncomplicated cataract surgery: a role for phacoemulsification energy and vitreoretinal interface status?. Eur J Ophthalmol. 25(3), 192-7.
Anastasilakis, A. D., Polyzos S. A., Delaroudis S., Toulis K. A., Mandanas S., Avgerinidou C., et al. (2012).  Long-term effects of thyroid fine-needle biopsy on the thyroid-related biochemical parameters.. Int J Clin Pract. 66(6), 602-9.
Anastasilakis, A. D., Toulis K. A., Goulis D. G., Polyzos S. A., Delaroudis S., Giomisi A., et al. (2009).  Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.. Horm Metab Res. 41(10), 721-9.
Anastasilakis, A. D., Polyzos S. A., Saridakis Z. G., Kynigopoulos G., Skouvaklidou E. C., Molyvas D., et al. (2014).  Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition.. J Clin Endocrinol Metab. 99(9), 3247-55.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Pavlidou V., Koukoulis G., et al. (2008).  Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.. Eur J Endocrinol. 158(3), 411-5.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Saridakis Z. G., Digkas D., Bisbinas I., et al. (2015).  Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.. Osteoporos Int. 26(10), 2521-7.
Anastasilakis, A. D., Polyzos S. A., Makras P., Savvides M., Sakellariou G. T., Gkiomisi A., et al. (2014).  Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.. Horm Metab Res. 46(2), 145-9.
Anastasilakis, A. D., Polyzos S. A., Makras P., Kampas L., Valeri R. Maria, Kyriakoulis D., et al. (2012).  Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature.. Hormones (Athens). 11(4), 419-27.
Anastasilakis, A. D., Polyzos S. A., & Toulis K. A. (2011).  Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge.. Curr Opin Endocrinol Diabetes Obes. 18(6), 383-8.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Savvides M., Papatheodorou A., et al. (2013).  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.. Osteoporos Int. 24(7), 2127-32.
Anastasilakis, A. D., Polyzos S. A., Goulis D. G., Slavakis A., Efstathiadou Z., Kita M., et al. (2008).  Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis.. Endocr J. 55(3), 613-6.
Anastasilakis, A. D., Polyzos S. A., Kitridis D., Makras P., Yavropoulou M. P., Palermo A., et al. (2021).  Ιrisin levels in postmenopausal women with an incident hip fracture.. Endocrine. 73(3), 719-722.
Anastasilakis, A. D., Polyzos S. A., Vorkas P. A., Gkiomisi A., Yavropoulou M. P., Rauner M., et al. (2023).  Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study.. J Clin Med. 12(16), 
Anastasilakis, A. D., Toulis K. A., Polyzos S. A., & Terpos E. (2009).  RANKL inhibition for the management of patients with benign metabolic bone disorders.. Expert Opin Investig Drugs. 18(8), 1085-102.
Anastasilakis, A. D., Polyzos S. A., Delaroudis S., Bisbinas I., Sakellariou G. T., Gkiomisi A., et al. (2012).  The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.. Clin Endocrinol (Oxf). 77(6), 816-22.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Appelman-Dijkstra N. M., Ntenti C., Mandanas S., et al. (2021).  Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.. Calcif Tissue Int.
Anastasilakis, A. D., Polyzos S. A., Makras P., Rauner M., Sonnleitner L., Hawa G., et al. (2019).  Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.. J Musculoskelet Neuronal Interact. 19(3), 253-257.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Anastasilakis, A. D., Polyzos S. A., Makras P., Aubry-Rozier B., Kaouri S., & Lamy O. (2017).  Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.. J Bone Miner Res. 32(6), 1291-1296.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.
Anastasilakis, A. D., Savvides M., Polyzos S. A., Georgopoulos C., & Delaroudis S. (2010).  Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.. J Bone Miner Metab. 28(1), 108-10.
Anastasilakis, A. D., Polyzos S. A., Karathanasi E., & Efstathiadou Z. (2011).  Coincidence of severe primary hyperparathyroidism and primary hypothyroidism in a postmenopausal woman with low bone mass--initial conservative management.. J Musculoskelet Neuronal Interact. 11(1), 77-80.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Koukoulis G. N., Efstathiadou Z., et al. (2008).  Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.. Int J Clin Pract. 62(6), 919-24.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.